Jounce Therapeutics, Inc. (JNCE) is a clinical stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long‑lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient. Jounce’s lead product candidate, JTX-2011, is a monoclonal antibody that binds to and activates ICOS and is currently in a Phase 1/2 trial.
This role will guide efforts in the generation of biologic leads derived from discovery and optimization platforms for the development of novel therapeutics. The Head of Protein Engineering will manage a team of scientists in support of therapeutic programs focused in immuno-oncology. This role requires expertise in antibody generation, screening, engineering and optimization, biologic topologies, platform technologies, and developability assessment for lead candidate selection.
To apply, please visit https://careers-jouncetx.icims.com